Sanofi India
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Sanofi India's recent strategic transformation, particularly its focus on maximizing the diabetes franchise, has led to a robust 17% growth in this segment during H1 2026. Management's emphasis on operational efficiency and the integration of AI and digital tools to enhance patient experiences are expected to support revenue growth and margin stability. However, challenges remain in the partnership business and export markets, particularly in Australia, which could impact overall performance. Vista's forecast reflects an improving revenue outlook, with margins expected to remain stable, aligning with the company's fair valuation. The favorable currency depreciation is anticipated to benefit export revenues, while the strong demand for chronic therapies underpins growth. Nevertheless, rising input costs and pricing pressures in key markets pose potential headwinds. Over the next 12-24 months, key opportunities include the expansion of the diabetes portfolio and the utilization of the Goa site for specialized manufacturing, while watchpoints include the performance of the partnership business and export challenges
Why We Like This Stock
- Strong 17% growth in the diabetes franchise driven by successful product adoption
- Integration of AI and digital tools enhances operational efficiency and patient engagement
- Favorable currency depreciation is expected to boost export revenues
Things To Watch Out For
- Structural challenges in the partnership business and export markets, particularly in Australia
- Rising input costs and pricing pressures in key markets may impact profitability
- Mixed performance across segments could lead to volatility in revenue growth
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,851 | 2,013 | 1,837 | 1,877 | 1,933 |
| Profit Before Tax (Cr.) | 828 | 469 | 472 | 484 | 498 |
| PBT Margin | 29.0% | 23.3% | 25.7% | 25.8% | 25.8% |
| Net Profit (Cr.) | 590 | 435 | 342 | 348 | 358 |
| Earnings Per Share | 256.5 | 189.1 | 148.7 | 151.3 | 155.7 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.